Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
about
Magnetic resonance imaging in psoriatic arthritis: a review of the literatureEfficacy of infliximab on MRI-determined bone oedema in psoriatic arthritisClinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabGolimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trialsSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisUpdating the OMERACT filter: implications for imaging and soluble biomarkersAnti-TNF-alpha therapy in ankylosing spondylitis.Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis.The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology.Discovertebral (Andersson) lesions in severe ankylosing spondylitis: a study using MRI and conventional radiography.Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials.International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitisUpdate on the treatment of ankylosing spondylitis.Spondyloarthritides: evolving therapiesNatural history and clinical significance of MRI-detected bone marrow lesions at the knee: a prospective study in community dwelling older adults.Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systemsRadiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy.Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imagingAssessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences.Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)What is MRI bone oedema in rheumatoid arthritis and why does it matter?First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.ASAS/EULAR recommendations for the management of ankylosing spondylitis.Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases.Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different?Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care.Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE studyInfliximab for the treatment of ankylosing spondylitis.Therapy of ankylosing spondylitis--a review. Part I: Conventional medical treatment and surgical therapy.Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides.How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?Pharmacological management of undifferentiated spondyloarthropathies.Vertebral body corner oedema vs gadolinium enhancement as biomarkers of active spinal inflammation in ankylosing spondylitis.Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.Early diagnosis of spondyloarthritis.Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.Clinimetric properties of the ASAS health index in a cohort of Italian patients with axial spondyloarthritis.
P2860
Q22000866-B0F66AEF-0A8C-4ABE-B0A1-748D66EDF596Q24674877-9B60583C-AF71-45A5-9912-9514DC17F9EFQ24816557-9E45260D-B3D0-4216-BF3A-CA9381C67F50Q26738520-E4A49F49-B8F2-4274-9F54-412E895DD746Q26852081-4042E03A-2D2D-481C-B600-B45C6C109D3AQ27014889-5062F24F-1C97-4589-A736-33A488F05D03Q33204138-C87176AF-A2F4-4D22-AC5B-DEB4A9EB99BEQ33275865-10F21C06-8A65-4E7E-8FEB-82A6A2BD7742Q33710428-5684A0FE-8438-44F0-A7CB-64B1971242FFQ34268747-05F09B40-A732-45B1-979A-690D9CA5F101Q34403448-54193FBA-8D68-41ED-90ED-52F0BF312AC4Q34536278-CFD30E8E-DF21-4AEE-B810-D95B9DDFD1AFQ34592673-2AB09DF0-6B52-431F-9801-BC5D01B65D27Q34613907-454F7C53-3D10-4D8A-B760-218BACE37466Q34614067-18406A79-0B79-478D-841F-1640E072416CQ35554218-7303DB8B-C9C9-4FC6-9B39-F00B6CEB5CB4Q35554475-C26FD9A3-27D9-4DE7-90ED-E06B1DC86030Q35554794-142F7543-B599-4DA5-B004-80CB7F2A34F2Q35554918-FFD69C3B-952C-41C2-8425-451FB3C366F3Q35555451-2ACACBE6-98C5-4913-8B6A-7D52F306B672Q35555465-CF56FCEC-7998-43C9-9C81-46004EFCC0E0Q35555833-30D023BD-2C0D-4581-88AB-D62961D2E923Q35605461-D6312CC5-D05B-4F97-9D1C-D50FA87154DCQ35630037-AD120407-5D7A-452A-95D0-890313D6CBEEQ35636900-9488BE5B-0587-4C2C-BF97-70B1309A3ABCQ35637012-FE55C392-6625-4BFA-895A-7859811A39F7Q35637293-3DB8408E-48FC-4E6E-AC4F-6760DF8B5469Q35638233-BBA99126-C41A-4F19-B69D-D93049D4FD1EQ35940404-890527CB-CB1E-4BD8-9DF2-F6DDB8BB296CQ36020178-24351F51-F6E5-4F7B-8320-9F2AAB070ED5Q36210882-13B6E58C-A108-4D08-A364-5D6D8E5E5DB1Q36226397-5ED0F7DD-2E22-4C66-B2C6-2E536AB098A9Q36245711-85DAFDF1-110E-4E29-A366-D803E317B319Q36292652-E316A810-E780-4038-B3F7-F7D8238A80C9Q36349645-016B0A5A-D888-4E03-AA8A-D1A6F0BB76CCQ36365524-B3EADFF6-C67F-49A6-B696-E46326E7C30FQ36458447-92AC4298-0DBD-420D-B4A2-768D6201E1FCQ36611042-77777DE7-25EB-47DC-87BA-02DEBF987BDAQ36773202-7DBF2232-07AB-4EFB-A0BF-1B47DF3126A9Q36907291-0E867BA7-E78E-4955-8FC5-D51BD94B65A6
P2860
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Magnetic resonance imaging exa ...... ation of a new scoring system.
@en
Magnetic resonance imaging exa ...... ation of a new scoring system.
@nl
type
label
Magnetic resonance imaging exa ...... ation of a new scoring system.
@en
Magnetic resonance imaging exa ...... ation of a new scoring system.
@nl
prefLabel
Magnetic resonance imaging exa ...... ation of a new scoring system.
@en
Magnetic resonance imaging exa ...... ation of a new scoring system.
@nl
P2093
P356
P1476
Magnetic resonance imaging exa ...... ation of a new scoring system.
@en
P2093
Baraliakos X
Rudwaleit M
Van Der Heijde D
P304
P356
10.1002/ART.10883
P577
2003-04-01T00:00:00Z